NASDAQ · MLND
Millendo Therapeutics, Inc.
Healthcare · Biotechnology
$1.06
Down-$0.06 (-5.36%)
Updated Aug 22, 2026, 7:47 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.15M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 1.91M
- Avg. volume
- 140.98K
Price performance
MLND price history
1M range · 0 trading sessions · Daily adjusted prices
MLND does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest MLND news
The latest Smart Investors Daily articles mentioning MLND.
Stock researchCompany · Overview
MLND research
Overview
Company profile and research snapshot.
Company profile
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 6, 2021 | Ladenburg Thalmann | Neutral | — |
| Jan 6, 2021 | SVB Leerink | Market Perform | — |
| May 29, 2020 | Citigroup | Buy | — |
| Apr 7, 2020 | Oppenheimer | Perform | — |
| Mar 24, 2020 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
